E-ISSN 2534-9821
 

Case Report 


Acquired factor VIII inhibitor following therapy with pembrolizumab in a patient with lung cancer

Gary W Takahashi.

Abstract
An elderly patient with metastatic lung adenocarcinoma presented with excessive bruising and persistent oozing several months after treatment with pembrolizumab, an immune checkpoint inhibitor. The cause of this hemostatic deficiency was identified as an inhibitor to factor VIII. Therapy with FEIBA (factor VIII inhibitor bypass activity), corticosteroids and immune gamma globulin resulted in clinically adequate improvement, but incomplete normalization of hemostatic parameters. Durable and complete restoration of aPTT and factor VIII activity occurred after subsequent treatment with rituximab, and supports its use as definitive therapy for acquired hemophilia resulting from the use of immune checkpoint inhibitor monoclonal antibodies.

Key words: acquired hemophilia, pembrolizumab, acquired factor VIII inhibitor, coagulopathy


 
ARTICLE TOOLS
Abstract
PDF Fulltext
How to cite this articleHow to cite this article
Citation Tools
Related Records
 Articles by Gary W Takahashi
on Google
on Google Scholar


How to Cite this Article
Pubmed Style

Takahashi GW, . Acquired factor VIII inhibitor following therapy with pembrolizumab in a patient with lung cancer. Int J Med Rev Case Rep. 2022; 6(20): 1-3. doi:10.5455/IJMRCR.172-1661296750


Web Style

Takahashi GW, . Acquired factor VIII inhibitor following therapy with pembrolizumab in a patient with lung cancer. https://www.mdpub.net/?mno=108642 [Access: December 05, 2023]. doi:10.5455/IJMRCR.172-1661296750


AMA (American Medical Association) Style

Takahashi GW, . Acquired factor VIII inhibitor following therapy with pembrolizumab in a patient with lung cancer. Int J Med Rev Case Rep. 2022; 6(20): 1-3. doi:10.5455/IJMRCR.172-1661296750



Vancouver/ICMJE Style

Takahashi GW, . Acquired factor VIII inhibitor following therapy with pembrolizumab in a patient with lung cancer. Int J Med Rev Case Rep. (2022), [cited December 05, 2023]; 6(20): 1-3. doi:10.5455/IJMRCR.172-1661296750



Harvard Style

Takahashi, G. W. & (2022) Acquired factor VIII inhibitor following therapy with pembrolizumab in a patient with lung cancer. Int J Med Rev Case Rep, 6 (20), 1-3. doi:10.5455/IJMRCR.172-1661296750



Turabian Style

Takahashi, Gary W, and . 2022. Acquired factor VIII inhibitor following therapy with pembrolizumab in a patient with lung cancer. International Journal of Medical Reviews and Case Reports, 6 (20), 1-3. doi:10.5455/IJMRCR.172-1661296750



Chicago Style

Takahashi, Gary W, and . "Acquired factor VIII inhibitor following therapy with pembrolizumab in a patient with lung cancer." International Journal of Medical Reviews and Case Reports 6 (2022), 1-3. doi:10.5455/IJMRCR.172-1661296750



MLA (The Modern Language Association) Style

Takahashi, Gary W, and . "Acquired factor VIII inhibitor following therapy with pembrolizumab in a patient with lung cancer." International Journal of Medical Reviews and Case Reports 6.20 (2022), 1-3. Print. doi:10.5455/IJMRCR.172-1661296750



APA (American Psychological Association) Style

Takahashi, G. W. & (2022) Acquired factor VIII inhibitor following therapy with pembrolizumab in a patient with lung cancer. International Journal of Medical Reviews and Case Reports, 6 (20), 1-3. doi:10.5455/IJMRCR.172-1661296750